Clopidogrel

Drug Profile

Clopidogrel

Alternative Names: DV-7314; Iscover; PCR 4099; Plavix; SR 25989C; SR 25990C

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sanofi-aventis
  • Developer Bristol-Myers Squibb; Sanofi
  • Class 2 ring heterocyclic compounds; Antiplatelets; Chlorobenzenes; Esters; Pyridines; Small molecules; Thienopyridines
  • Mechanism of Action Platelet ADP receptor antagonists; Platelet aggregation inhibitors; Purinergic P2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute coronary syndromes; Angina pectoris; Atherosclerosis; Cardiovascular disorders; Ischaemic heart disorders; Myocardial infarction; Peripheral arterial occlusive disorders; Stroke; Unstable angina pectoris
  • Phase III Coronary thrombosis
  • Discontinued Congenital heart defects

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 04 Oct 2012 Bristol-Myers Squibb intends to terminate its licence for clopidogrel in all countries except USA and Puerto Rico, effective 1 January 2013
  • 30 Sep 2012 Registered for Peripheral arterial occlusive disorders in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top